vs
Side-by-side financial comparison of Globalstar, Inc. (GSAT) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Twist Bioscience Corp is the larger business by last-quarter revenue ($103.7M vs $72.0M, roughly 1.4× Globalstar, Inc.). Globalstar, Inc. runs the higher net margin — -16.1% vs -29.4%, a 13.3% gap on every dollar of revenue. On growth, Globalstar, Inc. posted the faster year-over-year revenue change (17.6% vs 16.9%).
Globalstar, Inc. is an American telecommunications company that operates a satellite constellation in low Earth orbit (LEO) for satellite phone, low-speed data transmission and Earth observation. The Globalstar second-generation constellation consists of 25 satellites.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
GSAT vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $72.0M | $103.7M |
| Net Profit | $-11.6M | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | -0.5% | -31.7% |
| Net Margin | -16.1% | -29.4% |
| Revenue YoY | 17.6% | 16.9% |
| Net Profit YoY | 76.9% | 3.4% |
| EPS (diluted) | $-0.11 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $72.0M | $103.7M | ||
| Q3 25 | $73.8M | — | ||
| Q2 25 | $67.1M | — | ||
| Q1 25 | $60.0M | — | ||
| Q4 24 | $61.2M | — | ||
| Q3 24 | $72.3M | — | ||
| Q2 24 | $60.4M | — | ||
| Q1 24 | $56.5M | — |
| Q4 25 | $-11.6M | $-30.5M | ||
| Q3 25 | $1.1M | — | ||
| Q2 25 | $19.2M | — | ||
| Q1 25 | $-17.3M | — | ||
| Q4 24 | $-50.2M | — | ||
| Q3 24 | $9.9M | — | ||
| Q2 24 | $-9.7M | — | ||
| Q1 24 | $-13.2M | — |
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -0.5% | -31.7% | ||
| Q3 25 | 13.8% | — | ||
| Q2 25 | 9.2% | — | ||
| Q1 25 | -14.2% | — | ||
| Q4 24 | -6.9% | — | ||
| Q3 24 | 13.0% | — | ||
| Q2 24 | -2.4% | — | ||
| Q1 24 | -8.3% | — |
| Q4 25 | -16.1% | -29.4% | ||
| Q3 25 | 1.5% | — | ||
| Q2 25 | 28.6% | — | ||
| Q1 25 | -28.9% | — | ||
| Q4 24 | -82.1% | — | ||
| Q3 24 | 13.7% | — | ||
| Q2 24 | -16.0% | — | ||
| Q1 24 | -23.4% | — |
| Q4 25 | $-0.11 | $-0.50 | ||
| Q3 25 | $-0.01 | — | ||
| Q2 25 | $0.13 | — | ||
| Q1 25 | $-0.16 | — | ||
| Q4 24 | $-0.57 | — | ||
| Q3 24 | $0.00 | — | ||
| Q2 24 | $-0.01 | — | ||
| Q1 24 | $-0.01 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $447.5M | $197.9M |
| Total DebtLower is stronger | $483.8M | — |
| Stockholders' EquityBook value | $355.7M | $456.1M |
| Total Assets | $2.3B | $638.1M |
| Debt / EquityLower = less leverage | 1.36× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $447.5M | $197.9M | ||
| Q3 25 | $346.3M | — | ||
| Q2 25 | $308.2M | — | ||
| Q1 25 | $241.4M | — | ||
| Q4 24 | $391.2M | — | ||
| Q3 24 | $51.9M | — | ||
| Q2 24 | $64.3M | — | ||
| Q1 24 | $59.3M | — |
| Q4 25 | $483.8M | — | ||
| Q3 25 | $508.6M | — | ||
| Q2 25 | $491.5M | — | ||
| Q1 25 | $502.7M | — | ||
| Q4 24 | $511.4M | — | ||
| Q3 24 | $394.4M | — | ||
| Q2 24 | $393.1M | — | ||
| Q1 24 | $398.7M | — |
| Q4 25 | $355.7M | $456.1M | ||
| Q3 25 | $364.8M | — | ||
| Q2 25 | $360.9M | — | ||
| Q1 25 | $344.3M | — | ||
| Q4 24 | $358.9M | — | ||
| Q3 24 | $394.1M | — | ||
| Q2 24 | $383.0M | — | ||
| Q1 24 | $377.1M | — |
| Q4 25 | $2.3B | $638.1M | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $1.7B | — | ||
| Q3 24 | $917.6M | — | ||
| Q2 24 | $926.2M | — | ||
| Q1 24 | $917.0M | — |
| Q4 25 | 1.36× | — | ||
| Q3 25 | 1.39× | — | ||
| Q2 25 | 1.36× | — | ||
| Q1 25 | 1.46× | — | ||
| Q4 24 | 1.43× | — | ||
| Q3 24 | 1.00× | — | ||
| Q2 24 | 1.03× | — | ||
| Q1 24 | 1.06× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $175.9M | $-24.8M |
| Free Cash FlowOCF − Capex | — | $-34.8M |
| FCF MarginFCF / Revenue | — | -33.5% |
| Capex IntensityCapex / Revenue | — | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $175.9M | $-24.8M | ||
| Q3 25 | $236.0M | — | ||
| Q2 25 | $157.9M | — | ||
| Q1 25 | $51.9M | — | ||
| Q4 24 | $340.7M | — | ||
| Q3 24 | $32.0M | — | ||
| Q2 24 | $36.7M | — | ||
| Q1 24 | $29.8M | — |
| Q4 25 | — | $-34.8M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -33.5% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 9.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 216.53× | — | ||
| Q2 25 | 8.22× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.23× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GSAT
| Services | $67.4M | 94% |
| Products | $4.6M | 6% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
